Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.40 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | DEGS1 | O15121 | 2/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3923988 | 0.80 | ALDH1A1 (0.46) | GRIN2BNPC1RAB9APAX8KLF5 | |
| SCHEMBL3928871 | 0.77 | HTR1F (0.38) | NPC1RAB9ASMN1; SMN2CNR2 | |
| SCHEMBL3923056 | 0.76 | RAB9A (0.48) | GRIN2BNPC1RAB9APAX8KLF5 | |
| SCHEMBL2033050 | 0.76 | DEGS1 (0.51) | GRIN2BNPC1RAB9APAX8KLF5 | |
| SCHEMBL3928435 | 0.76 | ADORA2A (0.43) | CNR2 | |
| SCHEMBL5346957 | 0.75 | MAPT (0.48) | NPC1RAB9APAX8KLF5ALDH1A1 | |
| SCHEMBL18291838 | 0.74 | RAB9A (0.47) | GRIN2BNPC1RAB9APAX8KLF5 | |
| SCHEMBL3925763 | 0.74 | KDR (0.47) | GRIN2BNPC1RAB9APAX8KLF5 | |
| SCHEMBL5343691 | 0.74 | RAB9A (0.47) | GRIN2BNPC1RAB9APAX8KLF5 | |
| SCHEMBL2611194 | 0.74 | RAB9A (0.47) | GRIN2BNPC1RAB9APAX8KLF5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101035762-B | Alkil-pyridines as 11-beta inhibitors for diabetes | HOFFMANN LA ROCHE | 2010-09-29 | — | — | CN | disclosed |
| US-7482341-B2 | N-(pyridin-2-yl)-benzenesulfonamides; antidiabetic agents for Type II Diabetes; obesity; 11beta-hydroxysteroid dehydrogenase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2009-01-27 | — | — | US | disclosed |
| CN-101035762-A | Alkil-pyridines as 11-beta inhibitors for diabetes | HOFFMANN LA ROCHE (CH) | 2007-09-12 | — | — | CN | disclosed |
| WO-2006037501-A9 | ALKIL-PYRIDINES AS 11-BETA INHIBITORS FOR DIABETES | HOFFMANN LA ROCHE (CH) | 2007-08-02 | — | — | WO | disclosed |
| EP-1799647-A1 | ALKIL-PYRIDINES AS 11-BETA INHIBITORS FOR DIABETES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006037501-A1 | ALKIL-PYRIDINES AS 11-BETA INHIBITORS FOR DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-13 | — | — | WO | disclosed |
| US-20060074237-A1 | N-(pyridin-2-yl)-benzenesulfonamides; hypotensive agents; antidiabetic agents for Type II Diabetes; obesity, eating disorders, dyslipidemia; 11beta-hydroxysteroid dehydrogenase inhibitors | HOFFMANN-LA ROCHE INC. | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074237-A1 | N-(pyridin-2-yl)-benzenesulfonamides; hypotensive agents; antidiabetic agents for Type II Diabetes; obesity, eating disorders, dyslipidemia; 11beta-hydroxysteroid dehydrogenase inhibitors | HSD3B1, HSD3B2, HSD11B2 | GRIN2B 1237/4885NPC1 682/4885RAB9A 2530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.